Integrating bevacizumab into the management of epithelial ovarian cancer: the controversy of front-line versus recurrent disease
about
Ovarian Cancer Molecular Stratification and Tumor Heterogeneity: A Necessity and a ChallengeB7-H4 as a potential target for immunotherapy for gynecologic cancers: a closer lookProfile of trebananib (AMG386) and its potential in the treatment of ovarian cancerOutcomes and prognoses of patients with ovarian cancer using bevacizumab: 6-year experience in a tertiary care hospital of northern Taiwan.New ways to successfully target tumor vasculature in ovarian cancer.AAV-mediated persistent bevacizumab therapy suppresses tumor growth of ovarian cancer.Bevacizumab: a review of its use in advanced cancer.Targeting the folate receptor: diagnostic and therapeutic approaches to personalize cancer treatments.Demethoxycurcumin inhibited human epithelia ovarian cancer cells' growth via up-regulating miR-551a.
P2860
Q26777846-244EE8A4-BFFD-4D15-926C-C3CEA80DC3A3Q26824446-0BD3D4A7-F6C8-453C-B274-EB2E1902824FQ26991997-2ED726E5-FA1A-4DD8-9F1E-418D44DEE01BQ33441574-E08349D1-4257-4549-921A-B5911F770F21Q35928220-8C1AD2F4-8357-4E27-992B-A7BE96E82524Q37374843-F9033C8D-A378-472D-88C4-97C72D416F2EQ38260176-265C56A3-FCF6-4DCF-B3D4-5683E397C520Q38524502-BBC0B8C3-D1FC-4FE3-A14D-697D64E2BE0DQ38710398-3B3FA22F-D1D7-431B-BE67-CA686F304BB4
P2860
Integrating bevacizumab into the management of epithelial ovarian cancer: the controversy of front-line versus recurrent disease
description
2013 nî lūn-bûn
@nan
2013 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Integrating bevacizumab into t ...... -line versus recurrent disease
@ast
Integrating bevacizumab into t ...... -line versus recurrent disease
@en
Integrating bevacizumab into t ...... -line versus recurrent disease
@nl
type
label
Integrating bevacizumab into t ...... -line versus recurrent disease
@ast
Integrating bevacizumab into t ...... -line versus recurrent disease
@en
Integrating bevacizumab into t ...... -line versus recurrent disease
@nl
prefLabel
Integrating bevacizumab into t ...... -line versus recurrent disease
@ast
Integrating bevacizumab into t ...... -line versus recurrent disease
@en
Integrating bevacizumab into t ...... -line versus recurrent disease
@nl
P2093
P356
P1433
P1476
Integrating bevacizumab into t ...... -line versus recurrent disease
@en
P2093
B. J. Monk
E. Pujade-Lauraine
R. A. Burger
P304
P356
10.1093/ANNONC/MDT472
P407
P478
24 Suppl 10
P577
2013-12-01T00:00:00Z